EP1916996A2 - Production of an oxaliplatin mixture and a container and a container set for said mixture - Google Patents
Production of an oxaliplatin mixture and a container and a container set for said mixtureInfo
- Publication number
- EP1916996A2 EP1916996A2 EP06776798A EP06776798A EP1916996A2 EP 1916996 A2 EP1916996 A2 EP 1916996A2 EP 06776798 A EP06776798 A EP 06776798A EP 06776798 A EP06776798 A EP 06776798A EP 1916996 A2 EP1916996 A2 EP 1916996A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- oxaliplatin
- acid
- solution
- concentration
- container
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 title claims abstract description 79
- 229960001756 oxaliplatin Drugs 0.000 title claims abstract description 79
- 238000004519 manufacturing process Methods 0.000 title claims abstract 3
- 239000000203 mixture Substances 0.000 title description 3
- 239000000243 solution Substances 0.000 claims abstract description 46
- 239000002253 acid Substances 0.000 claims abstract description 24
- 239000007864 aqueous solution Substances 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims description 32
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 13
- 230000002378 acidificating effect Effects 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
- 150000007522 mineralic acids Chemical class 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- 235000006408 oxalic acid Nutrition 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000003708 ampul Substances 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 235000019846 buffering salt Nutrition 0.000 claims description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 239000011261 inert gas Substances 0.000 claims description 2
- 229910017604 nitric acid Inorganic materials 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims 1
- 238000007865 diluting Methods 0.000 abstract 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SYPAAUOZTIBVHX-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;2-hydroxypropanoic acid Chemical compound CC(O)C(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O SYPAAUOZTIBVHX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940113115 polyethylene glycol 200 Drugs 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229940057847 polyethylene glycol 600 Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
Definitions
- EP 0 943 331 B1 describes a stable oxaliplatin solution with oxalic acid or an oxalic acid salt as buffer.
- the solution can be filled into an ampoule, glass vial (page 8, line 10), infusion bag or syringe. Disadvantage of this formulation is a certain toxicity of oxalic acid.
- WO 03/047 587 discloses a stable oxaliplatin solution in suitable containers (page 12, line 28) with lactic acid or a lactic acid salt as buffer.
- the present invention relates to the use of an acid to increase the solubility of oxaliplatin in an aqueous solution.
- the invention relates to a process for the preparation of an aqueous oxaliplatin solution in which oxaliplatinol is dissolved in water by adding an acid to an oxaliplatin concentration which increases over an acid-free aqueous oxaliplatin solution, in particular under otherwise identical conditions is.
- the present invention relates to a process for the preparation of a solution consisting of oxaliplatin, an acid and water, in which oxaliplatin is dissolved in water by adding an acid to an oxaliplatin concentration which is elevated over an acid-free aqueous oxaliplatin solution.
- oxaliplatin in the method of the present invention, can be dissolved in water by adding the acid to the highest oxaliplatin saturation concentration achievable with this acid.
- an oxaliplatin concentration which is in the range which is determined on the one hand by the saturation concentration of an acid-free aqueous oxaliplatin solution and on the other hand by the highest saturation concentration in the presence of the acid is defined and the acid is added until the predetermined concentration is reached.
- the solution is free from carbohydrate such as e.g. Lactose, glucose, maltose, fructose, galactose or dextrans (e.g., 10-70).
- carbohydrate such as e.g. Lactose, glucose, maltose, fructose, galactose or dextrans (e.g., 10-70).
- the solution is free of polyethylene glycol, e.g. Polyethylene glycol 200, 300, 400 and 600 added.
- an integer or half-integer (integer plus 1) oxaliplatin concentration of a customary concentration unit of measure preferably the unit of measure mg / ml or molar.
- an inorganic and / or organic acid can be used in the process according to the invention.
- At least one inorganic acid can be used from the group formed by sulfuric acid, nitric acid and phosphoric acid.
- sulfuric acid is used.
- At least one organic acid may be used from the group formed by citric acid, succinic acid, ascorbic acid, oxalic acid, lactic acid and malonic acid.
- Citric acid is preferably used.
- a buffering salt Furthermore, in the method according to the invention, it is additionally possible to use a buffering salt. Furthermore, in the method according to the invention, a pH of 1 to 7 and in particular 1.5 to 4 can be set.
- the container can be closed under an inert gas.
- a vial, a screw-cap bottle or an ampoule can be provided as a container.
- a vial as a bottle, which is designed as a single-dose or multi-dose container.
- Another embodiment of the invention relates to a container of aqueous oxaliplatin solution obtainable by the process according to the invention.
- Another embodiment of the invention relates to a container having an acidic oxaliplatin aqueous solution of an oxaliplatin concentration which is elevated relative to an acid-free oxaliplatin aqueous solution.
- a further embodiment of the invention relates to a container with an acidic aqueous oxaliplatin solution with the highest oxaliplatin saturation concentration, which is achievable with the aid of this acid, or with the highest for the acid characteristic oxaliplatin saturation concentration.
- a further embodiment of the invention relates to a container with an acidic aqueous oxaliplatin solution having an integer or half integer (integer plus M) oxaliplatin concentration of a conventional concentration unit, preferably the unit mg oxaliplatin / ml solution or mg oxaliplatin / mg solution or molar.
- a further embodiment of the invention relates to a set of or containers according to the invention each having an acidic oxaliplatin aqueous solution having an integer or integer (integer plus M) oxaliplatin concentration of a conventional concentration unit, preferably mg oxaliplatin / ml Solution or mg oxaliplatin / mg solution or molar.
- an embodiment of the invention relates to a set of or containers according to the invention each having an acidic aqueous oxaliplatin solution with an integer or half integer (integer plus M) oxaliplatin concentration of a conventional concentration unit, preferably the unit mg oxaliplatin / ml Solution or mg oxaliplatin / mg solution or molar, whereby the oxaliplatin concentration of at least one container deviates from the concentration of the other container (s).
- the present invention further comprises the solutions prepared according to one of the described methods.
- 5 examples are used to tabulate the increased oxaliplatin solubility in the presence of acid.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Herstellung einer Oxaliplatin-Lösung und Behälter sowie Behälter-Set mit der Lösung Preparation of an oxaliplatin solution and container and container set with the solution
EP 0 943 331 Bl beschreibt eine stabile Oxaliplatin-Lösung mit Oxalsäure oder einem Oxalsäuresalz als Puffer. Die Lösung kann in eine Ampulle, Vial aus Glas (Seite 8 Zeile 10) , Infusionsbeutel oder Spritze gefüllt werden. Nachteil dieser Formulierung ist eine gewisse Toxizität der Oxalsäure.EP 0 943 331 B1 describes a stable oxaliplatin solution with oxalic acid or an oxalic acid salt as buffer. The solution can be filled into an ampoule, glass vial (page 8, line 10), infusion bag or syringe. Disadvantage of this formulation is a certain toxicity of oxalic acid.
WO 03/047 587 offenbart eine stabile Oxaliplatin-Lösung in geeigneten Behältern (Seite 12 Zeile 28) mit Milchsäure oder einem Milchsäuresalz als Puffer.WO 03/047 587 discloses a stable oxaliplatin solution in suitable containers (page 12, line 28) with lactic acid or a lactic acid salt as buffer.
In US 2003/0 109 515 Al wird eine stabile Oxaliplatin-Lösung in geeigneten Behältern (Ziffer [0060] ) mit Malonsäure oder einem Malonsäuresalz als Puffer beschrieben.US 2003/0 109 515 A1 describes a stable oxaliplatin solution in suitable containers (Item [0060]) with malonic acid or a salt of malonic acid as buffer.
Überraschenderweise wurde festgestellt, dass sich die Konzentration einer wässerigen Oxaliplatin-Lösung mit einer Säure auf einen Wert einstellen läßt, der gegenüber der Konzentration einer säurefreien Lösung erhöht ist.Surprisingly, it was found that the concentration of an aqueous oxaliplatin solution with an acid to a value can be adjusted, which is increased compared to the concentration of an acid-free solution.
Die vorliegende Erfindung betrifft somit gemäß einer Ausführungsform die Verwendung einer Säure zur Erhöhung der Löslichkeit von Oxaliplatin in einer wässrigen Lösung.Thus, in one embodiment, the present invention relates to the use of an acid to increase the solubility of oxaliplatin in an aqueous solution.
So betrifft die Erfindung gemäß einer weiteren Ausführungsform ein Verfahren zur Herstellung einer wässerigen Oxaliplatin-Lösung, bei dem man Oxaliplatin in Wasser durch Zugeben einer Säure bis zu einer Oxaliplatin-Konzentration löst, die gegenüber einer säurefreien wässerigen Oxaliplatin-Lösung insbesondere bei ansonsten gleichen Bedingungen erhöht ist.Thus, according to a further embodiment, the invention relates to a process for the preparation of an aqueous oxaliplatin solution in which oxaliplatinol is dissolved in water by adding an acid to an oxaliplatin concentration which increases over an acid-free aqueous oxaliplatin solution, in particular under otherwise identical conditions is.
Ferner betrifft die vorliegende Erfindung ein Verfahren zur Herstellung einer Lösung bestehend aus Oxaliplatin, einer Säure und Wasser, bei dem man Oxaliplatin in Wasser durch Zugeben einer Säure bis zu einer Oxaliplatin-Konzentration löst, die gegenüber einer säurefreien wässerigen Oxaliplatin-Lösung erhöht ist.Further, the present invention relates to a process for the preparation of a solution consisting of oxaliplatin, an acid and water, in which oxaliplatin is dissolved in water by adding an acid to an oxaliplatin concentration which is elevated over an acid-free aqueous oxaliplatin solution.
Bei dem erfindungsgemäßen Verfahren kann man Oxaliplatin in Wasser durch Zugeben der Säure bis zu der höchsten Oxaliplatin- Sättigungskonzentration lösen, die mit Hilfe dieser Säure erreichbar ist.In the method of the present invention, oxaliplatin can be dissolved in water by adding the acid to the highest oxaliplatin saturation concentration achievable with this acid.
Ferner kann man bei dem erfindungsgemäßen Verfahren eine Oxaliplatin-Konzentration vorgeben, die im Bereich liegt, der einerseits durch die Sättigungskonzentration einer säurefreien wässerigen Oxaliplatin-Lösung und andererseits durch die höchste Sättigungskonzentration in Gegenwart der Säure definiert ist, und die Säure zugibt, bis die vorgegebene Konzentration erreicht ist.Furthermore, in the method according to the invention, an oxaliplatin concentration which is in the range which is determined on the one hand by the saturation concentration of an acid-free aqueous oxaliplatin solution and on the other hand by the highest saturation concentration in the presence of the acid is defined and the acid is added until the predetermined concentration is reached.
Gemäß einer bevorzugten Ausführungsform wird bei dem Verfahren der vorliegenden Erfindung der Lösung kein Kohlenhydrat wie z.B. Lactose, Glucose, Maltose, Fructose, Galactose oder Dextrane (z.B. 10-70) zugefügt.In a preferred embodiment, in the method of the present invention, the solution is free from carbohydrate such as e.g. Lactose, glucose, maltose, fructose, galactose or dextrans (e.g., 10-70).
Gemäß einer weiteren bevorzugten Ausführungsform wird bei dem Verfahren der vorliegenden Erfindung der Lösung kein Polyethylenglycol wie z.B. Polyethylenglycol 200, 300, 400 und 600 zugefügt.According to another preferred embodiment, in the process of the present invention, the solution is free of polyethylene glycol, e.g. Polyethylene glycol 200, 300, 400 and 600 added.
Ferner kann man bei dem erfindungsgemäßen Verfahren eine ganzzahlige oder halbzahlige (ganze Zahl plus ^) Oxaliplatin- Konzentration einer üblichen Konzentrations-Maßeinheit einstellen, vorzugsweise der Maßeinheit mg/ml oder molar.Furthermore, in the method according to the invention, it is possible to set an integer or half-integer (integer plus 1) oxaliplatin concentration of a customary concentration unit of measure, preferably the unit of measure mg / ml or molar.
Ferner kann man bei dem erfindungsgemäßen Verfahren eine anorganische und/oder organische Säure verwenden.Furthermore, an inorganic and / or organic acid can be used in the process according to the invention.
So kann man mindestens eine anorganische Säure aus der durch Schwefelsäure, Salpetersäure und Phosphorsäure gebildeten Gruppe verwenden. Bevorzugt wird Schwefelsäure verwendet.Thus, at least one inorganic acid can be used from the group formed by sulfuric acid, nitric acid and phosphoric acid. Preferably, sulfuric acid is used.
Ferner kann man mindestens eine organische Säure aus der durch Citronensäure, Bernsteinsäure, Ascorbinsäure, Oxalsäure, Milchsäure und Malonsäure gebildeten Gruppe verwenden. Bevorzugt wird Citronensäure verwendet.Further, at least one organic acid may be used from the group formed by citric acid, succinic acid, ascorbic acid, oxalic acid, lactic acid and malonic acid. Citric acid is preferably used.
Ferner kann man bei dem erfindungsgemäßen Verfahren zusätzlich ein pufferndes Salz verwenden. Ferner kann man bei dem erfindungsgemäßen Verfahren einen pH- Wert von 1 bis 7 und insbesondere 1,5 bis 4 einstellen.Furthermore, in the method according to the invention, it is additionally possible to use a buffering salt. Furthermore, in the method according to the invention, a pH of 1 to 7 and in particular 1.5 to 4 can be set.
Ferner kann man bei dem erfindungsgemäßen Verfahren die hergestellte Lösung in einem Behälter abfüllen und den Behälter verschließen.Furthermore, in the method according to the invention, it is possible to fill the prepared solution in a container and close the container.
Ferner kann man bei dem erfindungsgemäßen Verfahren den Behälter unter einem Inertgas verschließen.Furthermore, in the method according to the invention, the container can be closed under an inert gas.
Ferner kann man bei dem erfindungsgemäßen Verfahren als Behälter eine Durchstechflasche (Vial) , eine Schraubverschlußflasche oder eine Ampulle vorsehen.Furthermore, in the method according to the invention, a vial, a screw-cap bottle or an ampoule can be provided as a container.
Ferner kann man bei dem erfindungsgemäßen Verfahren als Flasche eine Durchstechflasche verwenden, die als Eindosen- oder Mehrdosenbehälter ausgebildet ist.Furthermore, in the method according to the invention, it is possible to use a vial as a bottle, which is designed as a single-dose or multi-dose container.
Eine weitere Ausführungsform der Erfindung betrifft einen Behälter mit wässeriger Oxaliplatin-Lösung, erhältlich nach dem Verfahren gemäß der Erfindung.Another embodiment of the invention relates to a container of aqueous oxaliplatin solution obtainable by the process according to the invention.
Eine weitere Ausführungsform der Erfindung betrifft einen Behälter mit einer sauren wässerigen Oxaliplatin-Lösung einer Oxaliplatin-Konzentration, die gegenüber einer säurefreien wässerigen Oxaliplatin-Lösung erhöht ist.Another embodiment of the invention relates to a container having an acidic oxaliplatin aqueous solution of an oxaliplatin concentration which is elevated relative to an acid-free oxaliplatin aqueous solution.
Eine weitere Ausführungsform der Erfindung betrifft einen Behälter mit einer sauren wässerigen Oxaliplatin-Lösung mit der höchsten Oxaliplatin-Sättigungskonzentration, die mit Hilfe dieser Säure erreichbar ist, bzw. mit der höchsten für die betreffende Säure charakteristischen Oxaliplatin- Sättigungskonzentration.A further embodiment of the invention relates to a container with an acidic aqueous oxaliplatin solution with the highest oxaliplatin saturation concentration, which is achievable with the aid of this acid, or with the highest for the acid characteristic oxaliplatin saturation concentration.
Eine weitere Ausführungsform der Erfindung betrifft einen Behälter mit einer sauren wässerigen Oxaliplatin-Lösung mit einer ganzzahligen oder halbzahligen (ganze Zahl plus M) Oxaliplatin-Konzentration einer üblichen Konzentrations- Maßeinheit, vorzugsweise der Maßeinheit mg Oxaliplatin/ml Lösung oder mg Oxaliplatin/mg Lösung oder molar.A further embodiment of the invention relates to a container with an acidic aqueous oxaliplatin solution having an integer or half integer (integer plus M) oxaliplatin concentration of a conventional concentration unit, preferably the unit mg oxaliplatin / ml solution or mg oxaliplatin / mg solution or molar.
Eine weitere Ausführungsform der Erfindung betrifft einen Set von oder mit Behältern gemäß der Erfindung mit jeweils einer sauren wässerigen Oxaliplatin-Lösung mit einer ganzzahligen oder halbzahligen (ganze Zahl plus M) Oxaliplatin-Konzentration einer üblichen Konzentrations-Maßeinheit, vorzugsweise der Maßeinheit mg Oxaliplatin/ml Lösung oder mg Oxaliplatin/mg Lösung oder molar.A further embodiment of the invention relates to a set of or containers according to the invention each having an acidic oxaliplatin aqueous solution having an integer or integer (integer plus M) oxaliplatin concentration of a conventional concentration unit, preferably mg oxaliplatin / ml Solution or mg oxaliplatin / mg solution or molar.
Schließlich betrifft eine Ausführungsform der Erfindung einen Set von oder mit Behältern gemäß der Erfindung mit jeweils einer sauren wässerigen Oxaliplatin-Lösung mit einer ganzzahligen oder halbzahligen (ganze Zahl plus M) Oxaliplatin- Konzentration einer üblichen Konzentrations-Maßeinheit, vorzugsweise der Maßeinheit mg Oxaliplatin/ml Lösung oder mg Oxaliplatin/mg Lösung oder molar, wobei die Oxaliplatin- Konzentration mindestens eines Behälters von der Konzentration des (der) weiteren Behälters (Behälter) abweicht.Finally, an embodiment of the invention relates to a set of or containers according to the invention each having an acidic aqueous oxaliplatin solution with an integer or half integer (integer plus M) oxaliplatin concentration of a conventional concentration unit, preferably the unit mg oxaliplatin / ml Solution or mg oxaliplatin / mg solution or molar, whereby the oxaliplatin concentration of at least one container deviates from the concentration of the other container (s).
Die vorliegende Erfindung umfasst ferner die gemäß einem der beschriebenen Verfahren hergestellten Lösungen. Nachstehend wird mit 5 Beispielen die in Gegenwart von Säure erhöhte Oxaliplatin-Löslichkeit tabellarisch beschrieben.The present invention further comprises the solutions prepared according to one of the described methods. In the following, 5 examples are used to tabulate the increased oxaliplatin solubility in the presence of acid.
Wasser H2SO4 H3PO4 Citronen Milchsäure -säureWater H 2 SO 4 H 3 PO 4 Citric acid Lactic acid
PH 4,4 3, 5 1, 6 2 1 3,5PH 4.4 3, 5 1, 6 2 1 3,5
Molarität 0, 0025 0, 08 0 1 der SäureMolarity 0, 0025 0, 08 0 1 of the acid
Löslichkeit 5,7 6, 0 6 2 7 35 6,8 [mg/ml] Solubility 5.7 6, 0 6 2 7 35 6.8 [mg / ml]
Claims
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005038347A DE102005038347A1 (en) | 2005-08-11 | 2005-08-11 | Preparation of an oxaliplatin solution and container and container set with the solution |
| PCT/EP2006/007982 WO2007017291A2 (en) | 2005-08-11 | 2006-08-11 | Production of an oxaliplatin mixture and a container and a container set for said mixture |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1916996A2 true EP1916996A2 (en) | 2008-05-07 |
Family
ID=37179055
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP06776798A Withdrawn EP1916996A2 (en) | 2005-08-11 | 2006-08-11 | Production of an oxaliplatin mixture and a container and a container set for said mixture |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20100140131A1 (en) |
| EP (1) | EP1916996A2 (en) |
| DE (1) | DE102005038347A1 (en) |
| WO (1) | WO2007017291A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5929607B2 (en) * | 2012-08-06 | 2016-06-08 | ニプロ株式会社 | Oxaliplatin formulation |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004052877A1 (en) * | 2004-11-02 | 2006-05-04 | Ebewe Pharma Ges.M.B.H. Nfg.Kg | Stable aqueous formulations of a platinum derivative |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9804013D0 (en) * | 1998-02-25 | 1998-04-22 | Sanofi Sa | Formulations |
| WO2002047725A2 (en) * | 2000-12-12 | 2002-06-20 | Debiopharm S.A. | Pharmaceutical oxaliplatinum preparation for parenteral administration and method for obtaining same |
| CA2357955C (en) * | 2001-09-28 | 2008-11-18 | Itf Technologies Optiques Inc./Itf Optical Technologies Inc. | All-fiber depolarizer |
| US6476068B1 (en) * | 2001-12-06 | 2002-11-05 | Pharmacia Italia, S.P.A. | Platinum derivative pharmaceutical formulations |
| DE10314377A1 (en) * | 2003-03-28 | 2004-10-07 | Stada Arzneimittel Ag | Pharmaceutical composition useful for tumor therapy comprises water, oxaliplatin and an acid other than oxalic acid |
| EP2243480A1 (en) * | 2003-08-28 | 2010-10-27 | Mayne Pharma Pty Ltd | Pharmaceutical formulations comprising oxaliplatin and an acid. |
| US20060063833A1 (en) * | 2004-09-22 | 2006-03-23 | Edgar Schridde | Ready-to-use oxaliplatin solutions |
| DE102004063764A1 (en) * | 2004-12-29 | 2006-07-13 | Hexal Ag | Plastic bottle for oxaliplatin |
-
2005
- 2005-08-11 DE DE102005038347A patent/DE102005038347A1/en not_active Withdrawn
-
2006
- 2006-08-11 EP EP06776798A patent/EP1916996A2/en not_active Withdrawn
- 2006-08-11 US US12/063,531 patent/US20100140131A1/en not_active Abandoned
- 2006-08-11 WO PCT/EP2006/007982 patent/WO2007017291A2/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102004052877A1 (en) * | 2004-11-02 | 2006-05-04 | Ebewe Pharma Ges.M.B.H. Nfg.Kg | Stable aqueous formulations of a platinum derivative |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007017291A2 (en) | 2007-02-15 |
| DE102005038347A1 (en) | 2007-02-15 |
| US20100140131A1 (en) | 2010-06-10 |
| WO2007017291A3 (en) | 2007-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69523313T2 (en) | AQUEOUS RISPERIDONE COMPOSITIONS | |
| WO2002072080A2 (en) | Paracetamol solutions which are stable in storage and ready for infusion | |
| EP1255557B1 (en) | Stable, nasally, orally or sublingually applicable pharmaceutical preparation containing desmopressin | |
| DE2946724C2 (en) | ||
| DE3623620C2 (en) | ||
| EP2484350B1 (en) | Pharmaceutical preparation containing a complex of a salt of propofol and a cyclodextrin | |
| DE102004021532A1 (en) | Dispersion with insecticidal activity | |
| EP2626068B1 (en) | Paracetamol for parenteral administration | |
| AT399348B (en) | FORM- OR SPIDING MASS CONTAINING CELLULOSE AND USE OF CERTAIN SUBSTANCES FOR YOUR STABILIZATION | |
| EP1916996A2 (en) | Production of an oxaliplatin mixture and a container and a container set for said mixture | |
| DE60113255T2 (en) | NEW FORMULATIONS OF -G (A) -2,4-DISULFOPHENYL-N-TERT-BUTYLNITRONONE | |
| DE69632771T2 (en) | Human therapeutic albumin with low aluminum binding capacity | |
| DE3912153C1 (en) | Preventing deterioration of solns. by oxidn. - by feeding solns. in containers from which air has been expelled by injected protective gas | |
| AT392904B (en) | METHOD FOR PRODUCING A SOFT GEL CAPSULE INTENDED FOR THE ORAL ADMINISTRATION OF ETOPOSIDE | |
| CH651752A5 (en) | TWO-COMPONENT INJECTION PREPARATION. | |
| DE102004052877B4 (en) | Stable aqueous formulations of a platinum derivative | |
| WO2006072440A1 (en) | Plastic bottle for oxaliplatin solution | |
| EP3099330B1 (en) | Stable alcoholic solution of alprostadil | |
| DE2846831B1 (en) | Fertilizer pastes and processes for their production | |
| EP0108248B2 (en) | Aqueous nitroglycerine solution free of solubilizers | |
| DE3333278A1 (en) | METHOD FOR PREVENTING VINEGARATION IN BEVERAGES | |
| DE102004031538A1 (en) | Presentation form (obtainable by dissolving indibulin in or with a highly concentrated organic acid), useful to orally administer poorly soluble active compound indibulin, comprises a poorly soluble active compound indibulin | |
| DE4041543C2 (en) | Stabilization of ascorbic acid in strongly acidic solution | |
| DE102011122896A1 (en) | Method for manufacturing closed glass container, involves sealing one end of tapered tube in which solid materials are provided, and closing one end of straight rod tube connected with tapered tube, in which fluid in filled | |
| EP3755382A1 (en) | Process for producing a contrast agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20080206 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
| 17Q | First examination report despatched |
Effective date: 20081204 |
|
| DAX | Request for extension of the european patent (deleted) | ||
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20120301 |